Search
The Kids Research Institute Australia is currently in the process of implementing a new recruitment system. Please click the link below to view and
development officer communications
The Opportunity The Strep A and RHD Team at The Kids Research Institute Australia is looking for an Administration Officer to provide effective and
casual research assistant infectious diseases
The Opportunity The Kids Research Institute Australia is looking for a motivated individual who would like to join the Information Communication and
The Opportunity This is an exciting opportunity to develop your career whilst being a part of developing important health promotion messages. This is
The Role We are seeking an exceptional professional to join our team as a full-time Program Development Coordinator to drive the formation of an
The Opportunity You will provide effective and efficient administrative support for the designated researchers and research teams within the AREST CF
Research
Sex assigned at birth may modify health-related quality of life in children treated with peanut oral immunotherapyThe high burden of peanut allergy underscores the need for treatment options that improve patient health-related quality of life (HRQL). However, the modifying effect of sex assigned at birth on treatment-related outcomes remains poorly understood. We sought to investigate whether sex modifies treatment effect on the change in overall and subdomain HRQL during the PPOIT-003 trial.
Research
Heterogeneity and distribution characteristics of tertiary lymphoid structures predict prognostic outcome in esophageal squamous cell carcinomaTertiary Lymphoid Structures (TLSs) are ectopic lymphoid aggregates that form within the tumor microenvironment (TME) and are increasingly recognized as potential prognostic biomarkers in various cancers. However, the spatial heterogeneity and prognostic value of TLSs in esophageal squamous cell carcinoma (ESCC) remain poorly defined. This study aimed to characterize the spatial distribution patterns of TLSs and tumor-infiltrating lymphocytes (TILs), and to establish a refined prognostic model for ESCC patients in both surgery-only and neoadjuvant therapy cohorts.